AxoGen’s recent earnings call conveyed a generally positive outlook, underscored by robust revenue growth and strategic execution in high potential accounts and clinical training. Despite these ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the ...

Explore INmune Bio's Q2 2025 earnings call: new CEO, strategic shifts, XPro's Alzheimer's pause, CORDStrom advancements, and a focus on partnerships.

On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a ...

On July 30, the ECI wrote to the Chief Electoral Officer (CEO) of West Bengal to prepare the Booth Level Agents (BLA) list.

REGENXBIO speeds up RGX-202 pivotal enrollment for DMD, with commercial launch by 2027. Strong finances & regulatory milestones reinforce pipeline progress.

In recent years, the BLA has significantly expanded the scale and sophistication of its operations – conducting more than 150 attacks last year alone – culminating in this recent train hijacking.